Christopher Murray
Chief Tech/Sci/R&D Officer chez BLUEPRINT MEDICINES CORPORATION
Fortune : 3 M $ au 31/03/2024
Profil
Christopher K.
Murray is currently the Chief Technical Operations & Quality Officer at Blueprint Medicines Corp.
Prior to this, he worked at ARIAD Pharmaceuticals, Inc. for 13 years, where he held the position of Vice President-Technical Operations from 2013 to 2017.
Murray received his undergraduate degree from Hope College in 1984 and his graduate degree from The University of Chicago in 1990.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 07/03/2024 | 33 853 ( 0,06% ) | 3 M $ | 31/03/2024 |
Postes actifs de Christopher Murray
| Sociétés | Poste | Début |
|---|---|---|
| BLUEPRINT MEDICINES CORPORATION | Chief Tech/Sci/R&D Officer | 10/10/2017 |
Anciens postes connus de Christopher Murray
| Sociétés | Poste | Fin |
|---|---|---|
| ARIAD PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/05/2017 |
Formation de Christopher Murray
| Hope College | Undergraduate Degree |
| The University of Chicago | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BLUEPRINT MEDICINES CORPORATION | Health Technology |
| Entreprise privées | 1 |
|---|---|
ARIAD Pharmaceuticals, Inc.
 ARIAD Pharmaceuticals, Inc. BiotechnologyHealth Technology ARIAD Pharmaceuticals, Inc. operates as an oncology company, which engages in the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. The company was founded by Harvey J. Berger and James E. Rothman on January 8, 1992 and is headquartered in Cambridge, MA. | Health Technology |
